Checking Ovarian Reserve in Children Treated for Cancer
Observes whether a hormone blood test can predict later fertility problems in children with cancer.
Plain-language title generated from the registry record
Registry title: AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
Key facts
- Where
- Antwerp, Brussels, Leuven, Liège, and Montegnée, BelgiumSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 14 years old?
Source: NCT02595255, who can take part
Where in Belgium
- Universitair Ziekenhuis AntwerpenAntwerp, BelgiumTaking people
- Hôpital Universitaire Reine Fabiola (HUDERF)Brussels, BelgiumTaking people
- Universitair Ziekenhuis BrusselsBrussels, BelgiumTaking people
- Universitair Ziekenhuis LeuvenLeuven, BelgiumTaking people
- Centre Hospitalier Régional (CHR)-CitadelleLiège, BelgiumTaking people
- Centre Hospitalier Chrétien (CHC)- Clinique de l'espéranceMontegnée, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasme University Hospital
- Trial code
- NCT02595255
- Record updated
- 12 August 2026
- Original description
While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk.Read full original descriptionShow less
Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients
While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk.
The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.
Inclusion: Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005):; High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation; Moderate/Low risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma; No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.
Exclusion: CNS (central nervous system) irradiation, cerebral tumour; Current or previous ovarian disease/surgery; Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic/congenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction); Familial history of premature ovarian failure (no iatrogenic or surgical origins); Genetic/congenital disorders inducing mental retardation.